Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis

BACKGROUND: Immunotherapy for colorectal cancer has developed rapidly in the past decade. Many high-quality clinical trials examining the application of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer (mCRC) have been conducted in recent years. However, the clinical benefits, inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiao, Yang, Zhengyang, An, Yongbo, Liu, Yishan, Wei, Qi, Xu, Fengming, Yao, Hongwei, Zhang, Zhongtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944161/
https://www.ncbi.nlm.nih.gov/pubmed/35331250
http://dx.doi.org/10.1186/s12957-022-02549-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944161/
https://www.ncbi.nlm.nih.gov/pubmed/35331250
http://dx.doi.org/10.1186/s12957-022-02549-7

Ejemplares similares